Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age
Vaccine, Volume 12, No. 11, Year 1994
Notification
URL copied to clipboard!
Description
In two trials of measles vaccination in Guinea-Bissau, children were randomized to receive either the Edmonston-Zagreb (EZ) virus at age 4-8 months or, as a control group, a standard dose (5000 p.f.u.) of the Schwarz (SW) virus at 9-12 months. In the first trial a medium dose of EZ virus (40 000 p.f.u.) was used and in the later trial a high dose (150 000 p.f.u.). Pre- and postvaccination blood samples were analysed with a haemagglutination inhibition (HAI) test and an enzyme-linked immunosorbent assay (ELISA). For the ELISA the blood samples were collected on filter paper. Of 362 prevaccination specimens, 18 and 55%, respectively, were positive in the ELISA and HAI tests. At 18-20 months, the children who had received the EZ vaccine had a seropositivity of 91% by the ELISA method and one of 89% by the HAI method. The equivalent values for the SW group of children were 100 and 96% respectively. Antibody levels in the EZ group, as measured by either method, were significantly lower than the levels in the SW group. The serological results of the present study suggest that lowering the age at measles vaccination to below 9 months is feasible. However, further studies are needed to determine which virus strain, dosage and age at vaccination will prove to be optimal in countries where severe measles is common before the age of 9 months. © 1994.
Authors & Co-Authors
Jensen, Thøger Gorm
Denmark, Copenhagen
International Medical Cooperation Committee
Whittle, Hilton C.
Denmark, Copenhagen
International Medical Cooperation Committee
Gambia, Banjul
Medical Research Council Laboratories Gambia
Mordhorst, Carl Heinrich
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Statens Serum Institut
Pedersen, Ib Rode
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Københavns Universitet
Thaarup, Jesper
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Poulsen, Anja Grethe
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Sodemann, Morten
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Jakobsen, Marianne Skytte
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Brink, Lene
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Gansted, Uffe
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Permin, Astrid
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Institute of Health
Clotilde da Silva, Maria
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Epidemiology Research Unit
Aaby, Peter
Denmark, Copenhagen
International Medical Cooperation Committee
Denmark, Copenhagen
Københavns Universitet
Statistics
Citations: 16
Authors: 13
Affiliations: 6
Identifiers
Doi:
10.1016/0264-410X(94)90340-9
ISSN:
0264410X
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Randomised Control Trial
Study Locations
Guinea
Guinea-Bissau